AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06370325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodex
Description: Used to assess strength, endurance, power, and range of motion.
Study NCT06370325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex
Description: Used to assess strength, endurance, power, and range of motion.
Study NCT06507735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mannose
Description: Mannose is a sugar monomer that is important in the glycosylation of many proteins. The concentration of mannose in mammalian plasma is \~50-100 μM, which is primarily derived from N-glycan processing. Taking dietary mannose supplements can raise the levels of plasma mannose by 3- to 5-fold. There are currently no known adverse effects of mannose supplementation in humans.
Study NCT05536479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous stored mineralized dentin graft (ASMDG)
Description: Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction
Study NCT05536479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous fresh mineralized dentin graft (AFMDG)
Description: Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
Study NCT06029660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPEDE-FX RapidFill Implants
Description: Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
Study NCT06029660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EndoVascular Aneurysm Repair
Description: Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
Study NCT06029660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EndoVascular Aneurysm Repair
Description: Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
Study NCT05952310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cells (a new immunotherapy)
Description: It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells.
Study NCT05718739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AX6 6-axis logging accelerometer
Description: The device is collecting longitudinal movement data.
Study NCT05708521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery
Description: POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
Study NCT05708521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery
Description: SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
Study NCT04978415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peribulbar block versus subtenon's block
Description: Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery.
Study NCT06064617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lens
Description: Coopervision Biofinity Multifocal Lens
Study NCT06424002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosquirixs
Description: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.
Study NCT06424002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
Study NCT05138211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton assisted gait on a treadmill
Description: The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. - Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. - Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. - Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session.
Study NCT05556798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
Study NCT05556798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: 1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
Study NCT05556798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
Study NCT05803629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
Study NCT05803629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
Study NCT05855226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)
Description: The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
Study NCT05997901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varenicline healthbot
Description: The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
Study NCT05102942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Control Training Program
Description: The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).
Study NCT05102942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attentional Control Training Program
Description: The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).
Study NCT05239286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Description: All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia.
Study NCT05239286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia.
Study NCT05239286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluid managment
Description: Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
Study NCT05239286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVI dependant goal directed fluid therapy
Description: After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated.
Study NCT06258629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flowcytometry on bone marrow aspiration
Description: Flowcytometry on bone marrow aspiration
Study NCT05183581 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Feeling Hot sensor system
Description: The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
Study NCT03970031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSDC-0602K
Description: MSDC-0602K tablet
Study NCT03970031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet
Study NCT05913167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic nephrectomy
Description: laparoscopic nephrectomy
Study NCT04642430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Refer to Apixaban group
Study NCT04642430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Refer to Rivaroxaban group
Study NCT06162728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briquilimab
Description: Subcutaneous Administration
Study NCT06162728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT06540495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salaso Virtual Exercise Program
Description: Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
Study NCT06009029 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation(SBRT)
Description: SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects.
Study NCT06009029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (GLS-010)
Description: Zimberelimab (GLS-010),240mg d1 iv Q21D
Study NCT06467942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medicine and Lactobacillus
Description: combined drug group
Study NCT06467942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine
Description: Single Chinese medicine group
Study NCT05242458 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
Study NCT06590610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial pressure wave (RPW) - Intelect RPW2 Chattanooga
Description: RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
Study NCT05298033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole 2 % Topical Ointment
Description: Twice daily crisaborole 2% topical ointment
Study NCT05298033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 0.01% topical ointment
Description: Twice daily PF-07038124 0.01% topical ointment
Study NCT05298033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBUVB phototherapy
Description: Home narrow band UVB phototherapy exposure sessions 3 times per week
Study NCT05298033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBUVB phototherapy
Description: Home narrow band UVB phototherapy exposure sessions 3 times per week
Study NCT05298033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham phototherapy
Description: Non-NBUVB visible light radiation exposure sessions 3 times per week
Study NCT05298033 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham phototherapy
Description: Non-NBUVB visible light radiation exposure sessions 3 times per week
Study NCT05298033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Twice daily vehicle ointment
Study NCT05298033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Twice daily vehicle ointment
Study NCT05298033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Twice daily vehicle ointment
Study NCT06587516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular Warmup Program
Description: This intervention consists of a structured warm-up routine specifically designed to enhance neuromuscular function and balance. The program includes exercises such as two way forward lunge, single-leg balance, multidirectional lunges, single-leg hops forward and backward, and single-leg calf raises. Each exercise is aimed at improving proprioception, dynamic stability, and lower limb strength.
Study NCT06587516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Warmup Program
Description: This intervention involves a conventional warm-up program. It includes general stretching exercises and light jogging intended to prepare the body for physical activity.
Study NCT06586541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in attending team rounds
Description: Family members can participate both in-person and virtually, which can vary daily if desired. If the family member wishes to participate in-person, they will be invited to be present when the team rounds in the ICU. If the family member wishes to participate virtually, they will be provided with a personalized link by email to attend rounds.
Study NCT06467942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus
Description: Single Lactobacillus group
Study NCT06020079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation
Study NCT04109118 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
Description: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).